Aggregated News
After dozens of unsuccessful treatments, Eric Dishman started to suspect that his illness was due to something other than the rare kidney cancer he was diagnosed with in 1989. Five years ago, he had his whole genome sequenced, then gave the data to oncologists — and learned that he had a different type of cancer altogether.
He was treated successfully, and remains cancer-free. “I was an early prototype for precision medicine,” he says.
Dishman now leads the health and life-sciences division of microprocessor giant Intel in Banks, Oregon. He is also a member of a working group run by the US National Institutes of Health (NIH) for the Precision Medicine Initiative (PMI) — a US$215-million project to collect data on genomes, health records and physiological measurements from 1 million participants, to learn how genetics, environment and lifestyle influence disease risk and the effectiveness of treatments.
Next month, the group is expected to release a project plan. Observers are eager to learn its answer to a key question: how much information about disease risk, especially genetic data, will the project...
.jpg){kind=link}